A four-week clinical trial of sulforaphane in COPD patients failed to increase antioxidant gene targets of Nrf2 (such as HO-1) or to reduce oxidative stress and inflammation [123]. Here, HMOX1 is linked to chronic obstructive pulmonary disease.